CStone Pharmaceuticals
2616.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.14B
Close$
Share Statistics
| Market cap | $8.14 Billion |
|---|---|
| Enterprise Value | $7.11 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.31 |
| Beta | 0.25 |
| Outstanding Shares | 1,521,205,000 |
Return
| Return on Equity | -50.67% |
|---|---|
| Return on Assets | -31.85% |
| Return on Invested Capital | -39.55% |
Valuation & Multiples
| P/E Ratio | -16.05 |
|---|---|
| PEG | -19.06 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 11.92 |
| Enterprise Value to EBIT | -11.59 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.28 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
$158.17 M
Average shareholder expectationNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
$289.73 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About CStone Pharmaceuticals
102 employees
CEO: Jianxin Yang CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced immuno-oncology and precision medicines. Its mission is to address critical unmet medical needs for cancer p...